In GBM, lncRNA H19 may exert biological activity by targeting miR-193a-3p to regulate gene PLAU expression; KRT8, NGFR, and TCEA3 may stimulate novel strategies for immunotherapy of GBM patients. This evidence concerns the gene TCEA3 and glioblastoma.